Elutia Inc. (ELUT)
Nasdaq · Healthcare · Medical Devices
$0.8216+5.51%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $36.4M
- 52-week range
- $0.50 – $1.39
- 52-week change
- −11.17%
- EPS (trailing)
- −$0.64
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $12.3M (−15.03%)
- Net income
- $53.4M
- Operating margin
- −218.9%
- Diluted EPS
- $0.87
- Free cash flow
- −$46.7M
From the company’s annual report on SEC EDGAR.
About Elutia Inc.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents.
Headquarters: Gaithersburg, United States · 25 employees · elutia.com